ANAPTYSBIO, INC. (ANAB)

Every figure this model derived for ANAB, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-03-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 69,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-03-31
cash 286,455,000 CashAndCashEquivalentsAtCarryingValue 2026-03-31
current assets 316,109,000 AssetsCurrent 2026-03-31
current liabilities 41,702,000 LiabilitiesCurrent 2026-03-31
equity 12,747,000 StockholdersEquity 2026-03-31
interest expense 82,727,000 InterestPaidNet 2026-03-31
ocf 4,478,000 NetCashProvidedByUsedInOperatingActivities 2026-03-31
revenue 232,388,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-03-31
sbc 41,120,000 ShareBasedCompensation 2026-03-31

The ratios

The figures themselves rather than their scores — what somebody looking up ANAB on one particular measure came for.

RatioValue
cash operating margin35.48
current ratio7.58
current ratio reported7.58
dilution pct1.33
fcf margin1.9
growth cv1.61
interest cover0.49
operating margin17.56
owner earnings margin-15.8
revenue growth107.73
revenue growth per share105.01
rule of 40125.28
sbc pct revenue17.69

What to be careful about

What this model itself distrusts about ANAB's figures. Written by the derivation as it ran, not added afterwards.